Skip to main content
Funding Opportunities

Parkinson's Disease Clinical Therapeutics Pipeline Program


This program seeks to accelerate clinical therapeutic development of interventions that may reduce, slow or prevent disabling motor or non-motor symptoms of Parkinson’s disease not well managed by current treatments.

Funding will support clinical projects aimed at progressing promising interventions with strong preclinical packages into/through initial clinical assessment exploring pharmacokinetics and pharmacodynamics, safety/tolerability, or early proof of clinical efficacy. 

MJFF will prioritize proposals with the strongest translational potential, therapeutic rationale and patient value, fulfilling the following criteria: 

  • Selected therapeutic target/pathway or mechanism shows a strong biological rationale to be pursued as a therapeutic target in PD.  

  • The proposal emphasizes a translational biomarker development plan (where applicable), including measures to monitor target engagement/modulation, hypothesized mechanism of action and patient enrichment measures that can improve clinical trial design to de-risk further development. 

  • The proposal has a patient centered approach incorporating patient voice in the clinical development plan.   

For this round, MJFF will not consider:  

  • Pre-clinical applications.
  • Applications for target identification, proposing early discovery studies to identify new targets. 

  • Applications testing tool compounds or biological manipulations with no viable path for further drug optimization/development.   

The Parkinson’s Disease Clinical Therapeutics Pipeline Program works in two stages with the goal of offering applicants frequent chances to propose promising therapeutics: 

  1. Applicants may submit a pre-proposal application at any time for initial consideration by MJFF within three weeks from submissions.  

  2. Applicants whose pre-proposal is selected for further consideration will be invited to submit a full proposal to one of our upcoming review cycles, at least six weeks from the date of invitation. 

Applicants will be notified of a decision within 3 months of the full proposal submission period. Office hours are available for applicants invited to submit a full proposal to discuss program fit and proposal development.  

NOTE: Applicants are permitted to submit multiple, unique therapeutic pre-proposals but should NOT submit multiple pre-proposals supporting different stages or aspects of the same therapeutic development program. Applicants are also permitted and encouraged to re-submit a revised pre-proposal that addresses prior feedback provided by MJFF, if applicable. 

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.